Serevent (salmeterol), is now approved for chronic obstructive pulmonary disease (COPD)
March 1998
The long-acting beta-agonist, Serevent (salmeterol), is now approved for chronic obstructive pulmonary disease (COPD). It used to be approved just for asthma.
Serevent will be used as an alternative to Atrovent (ipratropium)...some patients will use them together.
One advantage is that Serevent is dosed BID...instead of TID to QID like Atrovent.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote